Boehringer Ingelheim and LEO Pharma Partner to Commercialize and Further Develop IL-36 Blocker Spesolimab (Spevigo)
Boehringer Ingelheim and LEO Pharma are teaming up to commercialize and advance the development of spesolimab (Spevigo), an interleukin-36 (IL-36) blocker approved to treat generalized pustular psoriasis (GPP).